Why did Q4 2023 Portfolio Receipts fall 31% year over year?

The decrease reflects the accelerated redemption of all outstanding Series A and Series B Biohaven Preferred Shares following Pfizer's acquisition of Biohaven in October 2022. Those payments were recorded in milestones and other contractual receipts in Q4 2022. Royalty receipts themselves increased 10% in the quarter.

What is Portfolio Receipts and how does it differ from Adjusted Cash Receipts?

Portfolio Receipts is now the company's key performance metric, defined as the sum of royalty receipts and milestones and other contractual receipts, net of payments to legacy non-controlling interests. The company states it produces the same amount as the previously reported Adjusted Cash Receipts, which will no longer be reported.

What is the 2024 financial outlook?

Royalty Pharma guided 2024 Portfolio Receipts of $2,600 million to $2,700 million, with royalty receipts growth of 5% to 9%. Payments for operating and professional costs are expected at 8% to 9% of Portfolio Receipts, and interest paid at about $160 million. The guidance excludes transactions announced after February 15, 2024.

How much did Royalty Pharma invest in new royalties in 2023?

The company announced new transactions of up to $4.0 billion in 2023, including upfront and potential milestone payments. Cash Capital Deployment was $2.2 billion for the year, of which $2,116 million was acquisitions of financial royalty assets. The Evrysdi royalty acquisition from PTC included a $1.0 billion upfront payment.

RPRX 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed February 15, 2024. Cited figures are marked; the original filing is the authoritative source.

Royalty Pharma plc (Nasdaq: RPRX) reported fourth quarter and full year 2023 results on February 15, 2024, as furnished in Exhibit 99.1, a press release.

Portfolio Receipts, now the company's key performance metric, were $736 million^a in Q4 2023, down 31% from the prior year period because of accelerated Biohaven payments received in Q4 2022. For full year 2023, Portfolio Receipts rose 9% to $3,049 million, driven by strong portfolio performance and new royalty acquisitions. Net cash provided by operating activities was $773 million in Q4 and $2,988 million for the full year, and Adjusted EBITDA was $2,806 million for 2023.

Royalty receipts grew 10% in the quarter and 8% for the year. The company announced new transactions of up to $4.0 billion^b in 2023 and reported Capital Deployment of $2.2 billion for the year. Cash and cash equivalents were $477 million and total debt principal was $6.3 billion at December 31, 2023.

The company also repurchased about 10 million shares for $305 million^c in 2023 under its $1.0 billion program. Management guided 2024 Portfolio Receipts to $2,600 million to $2,700 million, including expected royalty receipts growth of 5% to 9%, excluding future transactions. For investors, the key takeaways are the year-over-year growth in royalty receipts and the 2024 guidance, which excludes transactions announced after the release date.

The Q4 decline in headline receipts reflects a one-time item in the prior year rather than a deterioration in the royalty base. Interest paid is expected to be about $160 million^d in 2024.

02—Key points

Key Highlights

Full year 2023 Portfolio Receipts increased 9% to $3,049 million; Q4 2023 Portfolio Receipts decreased 31% to $736 million, reflecting accelerated Biohaven payments received in Q4 2022.
Royalty receipts grew 10% in Q4 2023 and 8% for full year 2023, to $2,449 million for the year.
Net cash provided by operating activities was $2,988 million for FY 2023 and $773 million for Q4 2023; Adjusted EBITDA (non-GAAP) was $2,806 million for FY 2023.
Announced new transactions of up to $4.0 billion in 2023; Capital Deployment totaled $2.2 billion for 2023, including $2,116 million in acquisitions of financial royalty assets.
Ended 2023 with $477 million in cash and cash equivalents and total debt principal of $6.3 billion.
2024 guidance: Portfolio Receipts of $2,600 million to $2,700 million, including expected royalty receipts growth of 5% to 9%, excluding future transactions; interest paid guided to $160 million.
Repurchased approximately 10 million Class A ordinary shares for $305 million in 2023 under a $1.0 billion multi-year program.

03—Questions

Frequently Asked Questions

Why did Q4 2023 Portfolio Receipts fall 31% year over year?
The decrease reflects the accelerated redemption of all outstanding Series A and Series B Biohaven Preferred Shares following Pfizer's acquisition of Biohaven in October 2022. Those payments were recorded in milestones and other contractual receipts in Q4 2022. Royalty receipts themselves increased 10% in the quarter.
What is Portfolio Receipts and how does it differ from Adjusted Cash Receipts?
Portfolio Receipts is now the company's key performance metric, defined as the sum of royalty receipts and milestones and other contractual receipts, net of payments to legacy non-controlling interests. The company states it produces the same amount as the previously reported Adjusted Cash Receipts, which will no longer be reported.
What is the 2024 financial outlook?
Royalty Pharma guided 2024 Portfolio Receipts of $2,600 million to $2,700 million, with royalty receipts growth of 5% to 9%. Payments for operating and professional costs are expected at 8% to 9% of Portfolio Receipts, and interest paid at about $160 million. The guidance excludes transactions announced after February 15, 2024.
How much did Royalty Pharma invest in new royalties in 2023?
The company announced new transactions of up to $4.0 billion in 2023, including upfront and potential milestone payments. Cash Capital Deployment was $2.2 billion for the year, of which $2,116 million was acquisitions of financial royalty assets. The Evrysdi royalty acquisition from PTC included a $1.0 billion upfront payment.

04—Continue

← View all 8-K filings